Codexis Inc. (NASDAQ:CDXS) traded today at a new 52-week high of $25.99. So far today approximately 106,000 shares have been exchanged, as compared to an average 30-day volume of 799,000 shares.
Codexis Inc. (NASDAQ:CDXS) defies analysts with a current price ($24.78) 43.6% above its average consensus price target of $13.99.
Over the past year, Codexis Inc. has traded in a range of $8.43 to $25.99 and is now at $24.78, 194% above that low.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins and developing biocatalyst products. The firm”s products and services include Screening and Evolution services, Enzymes, Screening Kits. It also develops protein engineering and biocatalyst platforms such as Codeevolver, Ketoreductases, Transminases, Imine reductases etc. The company operates in two business segment namely Performance Enzymes and Novel Biotherapeutics.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer